Chapter 03: Legal and Ethical Considerations Flashcards
In the development of a new drug by a pharmaceutical company, the researcher must ensure
that the participants in experimental drug studies do not have unrealistic expectations of the
new drug’s usefulness. What will the researcher include in the design of the study to prevent
bias that may occur?
a. A placebo
b. Health Canada approval
c. Informed consent
d. Efficacy information
a. A placebo
A member of an investigational drug study team is working with healthy volunteers whose
participation will help determine the optimal dosage range and pharmacokinetics of the drug.
In what type of study is the team member participating?
a. Phase I
b. Phase II
c. Phase III
d. Phase IV
a. Phase I
A patient has a prescription for a drug classified as Schedule F. What important information
should the nurse give this patient about obtaining refills for this medication?
a. No prescription refills are permitted.
b. Refills may be obtained via telephone order.
c. Refills are indicated by the prescriber.
d. The patient may have no more than six refills in a 12-month period.
c. Refills are indicated by the prescriber
A patient has been chosen to be a recipient of an investigational drug for heart failure and has
given informed consent. Which is indicated by the patient’s informed consent?
a. The patient has been informed of the possible benefits of the new therapy.
b. The patient will be informed of the details of the study as the research continues.
c. The patient will not be assured of receiving the actual drug during the experiment.
d. The patient has received an explanation of the study’s purpose, procedures, and the
benefits and risks involved.
d. The patient has received an explanation of the study’s purpose, procedures, and the
benefits and risks involved.
Which is the most significant part of legislation in regard to professional nursing practice?
a. Canada Health Act
b. Nursing Practice Act
c. Controlled Drugs and Substances Act
d. Personal Information Protection and Electronic Documents Act
b. Nursing Practice Act
What potential failure is identified when a patient with a documented penicillin allergy receives 1.2 g of benzylpenicillin IV? a. Failure to assess b. Failure to evaluate c. Failure to ensure safety d. Failure to identify the patient
c. Failure to ensure safety
Which statement correctly describes drugs in Part G, Part II of the Food and Drugs Act?
a. They are drugs with high potential for misuse that have an accepted medical use.
b. They are drugs with high potential for misuse that do not have an accepted medical
use.
c. They are medically accepted drugs that may cause mild physical or psychological
dependence.
d. They are medically accepted drugs with very limited potential for causing mild
physical or psychological dependence.
a. They are drugs with high potential for misuse that have an accepted medical use.
Which contributes to drug polymorphism?
a. The number of drugs ordered by the physician
b. The patient’s drug history
c. The patient’s age, sex, and body composition
d. Different dosage forms of the same drug
c. The patient’s age, sex, and body composition
Which best describes drug polymorphism?
a. Cultural and genetic effects on drug metabolism and excretion
b. Gender and cultural effects on drug absorption and distribution
c. Age or body composition effects on drug absorption or metabolism
d. Multidrug use resulting in impaired excretion
c. Age or body composition effects on drug absorption or metabolism
Which are elements of ethical principles in nursing and health care according to the Canadian
Nurses Association (CNA) Code of Ethics? (Select all that apply.)
a. Promoting justice
b. Maintaining anonymity
c. Demonstrating responsibility
d. Preserving dignity
e. Promoting health and well-being
a. Promoting justice
d. Preserving dignity
e. Promoting health and well-being
